Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Birth Defects Res A Clin Mol Teratol. 2015 Sep 26;106(1):47–54. doi: 10.1002/bdra.23455

Table 4.

Consent for Genetic Testing among Interviewed Participants by Visit Type and Institutional Review Board Consent Modification Level

P1 Father T1 T3-First T3-Prior Total
Level 1* 154/162
(95.1%)		 256/269
(95.2%)		 380/397
(95.7%)		 97/103
(94.2%)		 250/253
(98.8%)		 1137/1184
(96.0%)
Level 2* 71/85
(83.5%)		 112/128
(87.5%)		 160/170
(94.1%)		 37/42
(88.1%)		 116/119
(97/5%)		 496/544
(91.1%)
Level 3* 43/48
(89.6%)		 42/43
(97.7%)		 44/48
(91.7%)		 20/20
(100%)		 26/26
(100%)		 175/185
(94.6%)
Total 268/295
(90.8%)		 410/440
(93.2%)		 584/615
(95.0%)		 154/165
(93.3%)		 392/398
(98.5%)		 1808/1913
(94.5%)
*

Level 1 = no alterations to NICHD IRB-approved consent process; Level 2 = minimal alterations to NICHD IRB-approved consent process; and Llevel 3 = significant, substantive changes to consent process, particularly as applied to genetic testing.